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httpPerioperative management with antiplatelet and
statin medication is associated with reduced
mortality following vascular surgery
Randall R. De Martino, MD, MS,a,b Jens Eldrup-Jorgensen, MD,c Brian W. Nolan, MD, MS,a
David H. Stone, MD,a Julie Adams, MD,d Daniel J. Bertges, MD,d Jack L. Cronenwett, MD,a and
Philip P. Goodney, MD, MS,a on behalf of the Vascular Study Group of New England, Lebanon, NH;
Rochester, Minn; Portland, Me; and Burlington, Vt
Objective: Many patients undergoing vascular surgical procedures are not on appropriate medical therapy. This study
sought to examine the variation and impact of antiplatelet (AP) and statin therapy on early and late mortality in patients
undergoing vascular surgery in our region.
Methods: We studied all patients (n [ 14,489) undergoing elective carotid endarterectomy (n [ 6978), carotid stenting
(n[ 524), and suprainguinal (n[ 763) and infrainguinal bypass (n [ 3053), as well as patients with known coronary
risk factors undergoing open (n[ 1044) and endovascular (n[ 2127) abdominal aortic aneurysm repair from 2005 to
2012 in the Vascular Study Group of New England. Optimal medical management was deﬁned as treatment with both
AP and statin agents, preoperatively and at discharge. We analyzed temporal, procedural, and center variation of
medication use. Multivariable analyses were used to determine the adjusted impact of AP and statin therapy on 30-day
mortality and 5-year survival.
Results:Optimal medical management improved over the study interval (55% in 2005 to 68% in 2012; P trend < .01) with
carotid interventions having the highest rates of optimal medications use (carotid artery stenting, 78%; carotid endar-
terectomy, 74%) and abdominal aortic aneurysm repair in patients with known cardiac risk factors having the lowest
(open, 57%; endovascular aneurysm repair, 56%). Optimal medication use varied by center as well (range, 40%-86%).
Preoperative AP and statin use was associated with reduced 30-day mortality (odds ratio, 0.76; 95% conﬁdence interval
[CI], 0.5-1.05; P [ .09). AP and statin prescription at discharge was additive in survival beneﬁt with improved 5-year
survival (hazard ratio, 0.5; 95% CI, 0.4-0.7; P < .01) that was consistent across procedure types. Patients prescribed AP
and statin at discharge had 5-year survival of 79% (95% CI, 77%-81%) compared with only 61% (95% CI, 52%-68%;
P < .001) for patients on neither medication.
Conclusions: AP and statin therapy preoperatively and at discharge was associated with reduced 30-day mortality and an
absolute 18% improved 5-year survival after vascular surgery. However, one-third of patients are suboptimally managed
in real world practice. This demonstrates an opportunity for quality improvement that can substantially improve survival
after vascular surgery. (J Vasc Surg 2014;59:1615-21.)Peripheral arterial disease (PAD) and abdominal aortic
aneurysms (AAAs) are prevalent conditions encountered by
vascular surgeons with a high rate of associated cardiovas-
cular disease.1,2 Only 8% of patients undergoing major
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://dx.doi.org/10.1016/j.jvs.2013.12.013arteries.3 This results in a high incidence of clinical coro-
nary and cerebrovascular disease among those with PAD
and AAA.1,4 Patients with AAA have a two-fold higher
risk of heart attack and 1.8-fold higher risk of stroke
compared with population-based controls,5 and approxi-
mately 75% of those with PAD will ultimately die from car-
diovascular causes.1,6
Despite their high prevalence of cardiac disease, many
patients undergoing vascular surgery are not prescribed
appropriate cardiovascular medications, including anti-
platelet (AP) medications (aspirin or clopidogrel) and
HMG-CoA reductase inhibitors (statins). Of all PAD pa-
tients, 40% to 60% are not on AP agents, and 40% to
70% are not on statins.7,8 This is correlated with increased
risk of mortality, even in those with no known associated
coronary artery disease (CAD).8
The variation in optimal medication management
among patients undergoing vascular surgery in real world
practice has not been described. Further, the beneﬁt of
optimal medication utilization is not known in this patient
subset. The purpose of this study was to deﬁne the varia-
tion in perioperative medication usage among patients1615
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analyzed the effect of optimal medication utilization on
postoperative survival.
METHODS
Subjects and database. This is a retrospective analysis
of data collected prospectively by the Vascular Study Group
of New England (VSGNE), a regional cooperative quality
improvement initiative developed in 2002 to study regional
outcomes in vascular surgery.9 Of note, registry data are
compared with hospital claims in annual audits, and
missing cases are retrieved to yield a >99% complete cap-
ture rate for all tracked procedures.9 Mortality data is
supplemented by semiannual matching of registry data with
the Social Security Death Index (SSDI). Data from 2003
and 2004 was excluded since discharge statin use was not
tracked until 2005. We selected all patients from 2005 to
2012 undergoing their ﬁrst time interventions in the
VSGNE for carotid endarterectomy (CEA), carotid artery
stenting (CAS), infrainguinal and suprainguinal arterial
bypass, and AAA repair (open [oAAA] or endovascular
[EVAR]). This yielded our initial cohort of 17,806 pa-
tients. These patients were selected because multiple
guidelines support AP and statin use for cerebrovascular
disease and symptomatic PAD.1,6,10-12 Patients undergoing
AAA repair were only included if they had known coronary
risk factors that support both aspirin and statin use,13
including a history of CAD, hypertension, positive stress
test, prior coronary revascularization, a prior arterial bypass
or peripheral intervention, or prior carotid revasculariza-
tion. Only 366 (10%) of all eligible AAA repairs were
excluded. Of note, these excluded patients with AAA had
similar perioperative mortality, but slightly better overall
survival than the remaining AAA patients (78% vs 71% at
5 years). All cases were elective; urgent or emergent cases
were excluded (2263 emergent and 681 urgent). These
exclusion criteria were designed to provide a cohort of
patients with the potential to be placed on AP and statin
medications before elective surgery. Finally, patients were
removed from analysis for missing preoperative medication
data (n ¼ 5). This resulted in 14,489 patients with data
available for 30-day analysis (Fig 1). Our 5-year survival
analysis was based on the hypothesis that survival may be
affected by medications prescribed at discharge. Therefore,
we excluded patients from the 5-year survival analysis if
they died in-hospital postoperatively (n ¼ 111) or had
missing discharge medication data (n ¼ 629). This left
13,749 patients for 5-year survival analysis (Fig 1).
Statin use was deﬁned as being on any type of statin
medication at any dose. Patients were considered on AP
medication if they were on aspirin (any dose) or any
P2Y12a antagonist (commonly clopidogrel). Preoperative
medication use was deﬁned as taking the medication within
36 hours of surgery. Patients classiﬁed as being intolerant
to AP and statin were considered as not taking these med-
ications (only four patients were intolerant to any AP, and
181 were intolerant to statins). Patients were not assessedfor medication adherence at any point, and no serological
tests were done on drug efﬁcacy, lipid levels, or other
biochemical markers.
Long-term survival was determined from the VSGNE
database and by matching patient information with the
SSDI. There is no information on any patient’s cause of
death, only the time from the procedure until their death.
Patients not in the SSDI or not having a hospital record of
dying were considered alive with survival days ending at the
time of data harvest (December 2012). Deﬁnitions of med-
ical comorbidities in the VSGNE cohort have been previ-
ously published.14
Data collection and statistical analysis. Physicians,
nurses, or clinical data abstractors entered data prospec-
tively on clinical and demographic variables. Research ana-
lysts were blinded to patient, surgeon, and hospital identity.
The Committee for the Protection of Human Subjects at
DartmouthMedical School has approved the use of deiden-
tiﬁed data from VSGNE for research purposes.
Optimal medical management was deﬁned as AP and
statin use preoperatively and at discharge. Our primary out-
comes were 30-day death and 5-year survival. Patients were
stratiﬁed by their medication utilization (none, AP only,
statin only, or both). To study 30-day death, preoperative
variables were compared using c2 for categorical variables
with Fisher exact correction if event rates were low. A
two-sample t-test or Wilcoxon rank sum test was used to
compare normal or non-normal continuous data respec-
tively. Variables with a P value of <0.1 were included in a
backwards stepwise logistic regression analysis to identify
factors associated with 30-day death. For survival analysis,
univariate comparisons were made with log-rank or Cox
proportional hazards for categorical and continuous vari-
able respectively starting at 30 days to exclude events within
30 days. Variables of clinical signiﬁcance and those with a P
value of<0.1 by univariate survival analysis were included in
a backwards stepwise multivariable Cox proportional haz-
ards model to identify signiﬁcant predictors of long-term
mortality. Variables for both logistic and Cox models
were removed using the likelihood ratio test. Continuous
variables with nonlinear risk were categorized for analysis.
Age was categorized by quartiles. Probability values
of <0.05 were considered signiﬁcant. Analyses were done
using Stata release 11 (Stata Corp, College Station, Tex).
RESULTS
Patient population and medication variation. From
2005 to 2012, a total of 14,489 patients underwent their
ﬁrst elective procedure in the VSGNE, of which, 52% were
for carotid interventions, 26% arterial bypass, and 22%
AAA repair (Fig 2). Patients on average were 70 years of
age (standard deviation, 9.9) and male (66%). Prevalent
comorbidities included hypertension (89%) and history of
tobacco use (84%). Less common comorbidities included;
diabetes (32%), CAD (33%), chronic obstructive pulmonary
disease (COPD; 26%), and congestive heart failure (CHF;
10%; Table I).
Fig 1. Identiﬁcation patients in the Vascular Study Group of New England (VSGNE) for analysis. AAA, Abdominal
aortic aneurysm; AP, antiplatelet (aspirin or clopidogrel); CAS, carotid artery stenting; CEA, carotid endarterectomy.
Fig 2. Distribution of cases among patients undergoing primary
elective operation in the Vascular Study Group of New England
(VSGNE), 2005-2012. CAS, Carotid artery stenting; CEA, ca-
rotid endarterectomy; EVAR, endovascular aortic aneurysm repair;
Infra, infra-inguinal artery bypass; oAAA, open abdominal aortic
aneurysm repair; Supra, suprainguinal artery bypass.
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management (AP and statin preoperatively and at
discharge) increased, notably from 55% in 2005 to 70%
in 2009, after which it plateaued (P trend < .01; Fig 3).
The rate of optimal medication use varied by procedure.
Carotid interventions had the highest rate of medication
utilization (78% for CAS; 74% CEA) and AAA repair the
lowest (57% oAAA; 56% EVAR). Optimal medication use
after bypass procedures was intermediate (60% infraingui-
nal; 57% suprainguinal; Fig 4, a). Within each procedure,
there was wide variation in optimal medical management
across individual medical centers within the VSGNE
(Fig 4, b). As a result, there was wide center variation in
the use of optimal medical management across all proce-
dures, ranging from 40% to 86% of patients seen at each
center (Fig 5). Even when low volume centers (<100cases) were excluded, there was still wide variation (43%
to 76%; Supplementary Fig, online only).
Thirty-day mortality. During the study interval, 167
patients (1.2%) died within 30 days of surgery. This corre-
sponded to a mortality rate for CAS of 0.6%, CEA 0.5%,
oAAA 2.8%, EVAR 1.1%, suprainguinal 2.4%, and infrain-
guinal 1.8% bypasses. When analyzed by preoperative medi-
cation status (none, AP only, statin only, or both), patients
on both medications had the lowest 30-day mortality rate
(1.8% none; 1.1% AP only; 2.3% statin only; 0.9% both; P <
.001 across groups and none vs both P ¼ .02). However,
there was no statistical difference when patients on neither
medication were compared with AP only or statin therapy
only (P ¼ .1 and P ¼ .5, respectively). In multivariable
logistic analysis, AP and statin medication usage preopera-
tively was associated with a trend towards lower 30-day
mortality (odds ratio, 0.75; 95% conﬁdence interval [CI],
0.5-1.05; P ¼ .09; Table II). Other signiﬁcant factors asso-
ciated with 30-day mortality included increasing age, CAD,
CHF, COPD, non-independent living status, and being
on dialysis (Table II). Smoking status (current or former)
was not signiﬁcantly associated with 30-day mortality.
Five-year survival. Overall, the 5-year survival rate
was 76% (95% CI, 75%-78%). Survival was higher among
those discharged on both AP and statin therapy (79%; 95%
CI, 77%-81%) compared with patients on suboptimal
therapy (70%; 95% CI, 67%-73%; P < .001). This trend
persisted for each procedure when analyzed separately
(Supplementary Table, online only). When evaluated by
discharge medication status, patients on both agents had
the highest overall survival at 79% (95% CI, 77%-81%)
compared with neither medication (61%; 95% CI, 52%-
68%; P < .001). Patients on either medication had inter-
mediate survival of 74% (95% CI, 68%-79%) for statin only
and 72% (95% CI, 69%-75%) for AP only (P > .05 between
single agent only; Fig 6). In multivariable survival analysis,
patients discharged on both AP or statin medications had
an improved 5-year survival (statin hazard ratio [HR], 0.7;
Table I. Patient characteristics in the Vascular Study
Group of New England (VSGNE) undergoing ﬁrst time
elective procedures (2005-2012)
Patient characteristics (N ¼ 14,489) %
Mean age, years (SD) 70 (9.9)
Male 65.6
Smoking
Never 16.2
Former (>1 year) 49.5
Current (within 1 year) 34.3
Hypertension 88.9
Diabetes
No 68.4
Diet-controlled 5.7
Oral medications 15.6
Insulin 10.4
CAD
None 67.4
Prior MI 20.7
Stable angina 10.1
Unstable angina/recent MI 1.9
Any CABG/PTCA 31.2
CHF
None 90.2
Asymptomatic 5.9
Mild 3.1
Severe 0.8
COPD
No 74.0
Diagnosis, not treated 10.4
On medication 13.4
On oxygen 2.2
Dialysis 1.6
Creatinine >1.8 mg/dL 5.8
All stress tests
Not done 58.5
Normal 29.3
Abnormal 12.2
AP use 85.5
Intolerant <0.1
Statin 77.5
Intolerant 1.3
Beta-blockers
None 22.3
Perioperative 16.9
Chronic 58.9
Intolerant 1.1
Intraoperative only 0.8
AP, Antiplatelet medication (aspirin or clopidogrel); CABG, coronary artery
bypass graft; CAD, coronary artery disease; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction;
PTCA, percutaneous transluminal coronary angioplasty; SD, standard
deviation.
Fig 3. Use of optimal medication over time in the Vascular Study
Group of New England (VSGNE). Optimal medical therapy,
Taking antiplatelet (AP) and statin medication preoperatively and
at discharge.
Fig 4. a, Proportion of patients on optimal medical therapy across
procedures in the Vascular Study Group of New England
(VSGNE). b, Proportion of patients on optimal medical therapy
across procedures in the VSGNE. AAA, Abdominal aortic aneu-
rysm; CAS, carotid artery stenting; CEA, carotid endarterectomy;
EVAR, endovascular aortic aneurysm repair; Infra, infrainguinal
artery bypass; oAAA, open AAA repair; Supra, suprainguinal artery
bypass.
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with patients on neither medication (P < .001). Patients on
both AP and statin medications had the largest survival
beneﬁt (HR, 0.5; 95% CI, 0.4-0.7), even when adjusting
for age, comorbidities, and procedure (Table III). Other
factors that were associated with decreased 5-year survival
included patients’ age, smoking status, diabetes, CAD,
CHF, COPD, chronic renal disease, nonindependent living
status before operation, and a prior amputation or bypass
(Table III).DISCUSSION
Patients requiring vascular surgery carry a signiﬁcant
cardiac disease burden. PAD is a signiﬁcant cardiac risk fac-
tor, and most patients with symptomatic PAD will die from
their cardiac disease.1,6 Potentially underappreciated is that
Fig 5. Variation in optimal medical therapy across Centers in the
Vascular Study Group of New England (VSGNE) (2005-2012).
Table II. Multivariable model for 30-day death
Variable OR 95% CI P
Age, years 1.06 1.04-1.08 <.001
CAD 1.74 1.25-2.4 .001
CHF 1.78 1.21-2.62 .003
COPD 1.77 1.28-2.44 <.001
Nonindependent living preoperatively 3.78 2.04-7.03 <.001
Dialysis 4.36 2.48-7.68 <.001
Preoperative AP and statin 0.75 0.55-1.05 .09
Area under curve ¼ 0.76
AP, Antiplatelet agents (aspirin or clopidogrel); CAD, coronary artery dis-
ease; CHF, congestive heart failure; CI, conﬁdence interval; COPD, chronic
obstructive pulmonary disease; OR, odds ratio.
Fig 6. Five-year survival following surgery by discharge medica-
tion status. AP, Antiplatelet medication.
Table III. Multivariable factors associated with 5-year
survival following vascular surgical procedures
OR 95% CI P
Age, years
#63 1.0 (ref)
64-70 1.5 1.3-1.9 <.001
71-77 2.0 1.6-2.4 <.001
$78 4.0 3.3-4.9 <.001
Female 1.0 0.9-1.1 .83
Smoking status
Never 1.0 (ref)
Former (>1 year) 1.2 1.04-1.5 .014
Current (within 1 year) 1.3 1.1-1.6 .005
Diabetes
None 1.0 (ref)
Diet-controlled 1.1 0.89-1.41 .32
Oral medications 1.1 0.9-1.3 .09
Insulin 1.4 1.2-1.7 <.001
CAD
None 1.0 (ref)
Prior MI 1.2 1.1-1.4 .002
Stable angina 1.4 1.2-1.7 <.001
Unstable angina/recent MI 1 0.6-1.8 .87
CHF
None 1.0 (ref)
Asymptomatic 1.5 1.3-1.9 <.001
Mild 1.7 1.4-2.1 <.001
Severe 1.6 1.0-2.6 .03
COPD
None 1.0 (ref)
Diagnosis, not treated 1.2 1.0-1.4 .03
On medications 1.5 1.2-1.7 <.001
On oxygen 2.4 1.9-3.1 <.001
eGFR
$60 1.0 (ref)
40-59 1.1 1.0-1.3 .06
30-39 1.2 1.0-1.5 .04
<30 2.4 1.9-2.9 <.001
Missing 2.6 2.1-3.2 <.001
Nonindependent living status 2.0 1.4-2.8 <.001
Prior bypass 1.4 1.2-1.7 <.001
Prior amputation 1.5 1.1-2.2 .027
Discharge medication
None 1.0 (ref)
Statin 0.7 0.5-0.9 .008
AP 0.7 0.6-0.9 .005
Both 0.5 0.4-0.7 <.001
Procedure
CAS 1.0 (ref)
CEA 0.6 0.5-0.9 .002
oAAA 0.7 0.5-0.9 .03
EVAR 0.8 0.6-1.1 .13
Suprainguinal bypass 1.1 0.7-1.8 .73
Infrainguinal bypass 1.2 0.9-1.6 .13
AP, Antiplatelet medication (aspirin or clopidogrel); CAD, coronary artery
disease; CAS, cardiac artery stenting; CEA, carotid endarterectomy; CHF,
congestive heart failure; CI, conﬁdence interval; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular ﬁltration rate (mL/min/
1.73 m2); EVAR, endovascular aneurysm repair; MI, myocardial infarction;
oAAA, open OR, odds ratio.
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lar disease and mortality.5 Medical management for pa-
tients with symptomatic PAD and known cardiac disease
is well outlined and endorsed by several multidisciplinary
guidelines.1,6,10,12 This treatment includes the use of AP
and statin agents to reduce the incidence of cardiovascular
events in addition to glucose control in diabetics, smoking
cessation, and blood pressure control.1,6,10,13 This present
study has demonstrated that despite the known beneﬁts of
these agents, their use in clinical practice is associated withsigniﬁcant variation. Importantly, patients on optimal med-
ical therapy have lower perioperative mortality and an abso-
lute 18% improved 5-year survival. Such a survival
improvement is difﬁcult to improve in these patients, and
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repairing their AAA.
Despite the known beneﬁts of AP and statins, ensuring
that patients are on them may be difﬁcult. Even patients in
randomized controlled trials are not routinely on these
agents. Although the Bypass vs Angioplasty in Severe
Ischaemia of the Leg (BASIL) trial is several years old, pa-
tients had AP usage rates preoperatively of 54% and statin
use of 34%.15 Similarly, low use of AP agents was seen in
the Open vs Endovascular Repair (OVER) trial for AAA
repair.16 In comparison, recent carotid studies have had
much higher adherence to AP and statin agents. In the Ca-
rotid Revascularization Endarterectomy vs Stenting Trial
(CREST), >90% of patients were on AP agents before
and after their procedure,17 and >85% of patients were
on lipid-lowering agents.18 These ﬁndings mirror our
ﬁnding that patients undergoing carotid interventions are
more likely to be on optimal medical management
compared with patients with PAD or AAA in the VSGNE.
Undertreatment of PAD has gained recent attention.19
In the National Health and Nutrition Examination Survey
(NHANES), it is estimated that approximately 7 million
Americans have PAD. Yet, only 30% are on statin medica-
tions and 35% on aspirin. This leaves over 4.5 million
American undertreated for their PAD. Patients on multi-
drug therapy had a 65% adjusted reduction in mortality.8
A similar Danish longitudinal study demonstrated that
although use of AP and statins increased in the early
2000s, only 53% of patients with PAD were on an aspirin,
and 40% were on a statin.7 Compared with patients with
known CAD, patients with PAD were less likely to be on
these protective medications. This highlights the impor-
tance of recognizing PAD as a major risk factor for cardio-
vascular events and a stimulus to initiate proper therapy.
Efforts to improve medication utilization are underway
nationally. The Society for Vascular Surgery has sponsored
a National Quality Forum measure for AP use following ca-
rotid interventions.20 Additionally, the Department of
Health and Human Services has sponsored the Million
Hearts initiative. The goal of this initiative is to prevent
one million heart attack and strokes by 2017 by ensuring
appropriate medical treatment and smoking cessation for
those with cardiovascular disease.21
Despite these national efforts, patient care coordination
is a result of complex factors such as practice patterns,
referrals, health systems, insurance, compliance, and socio-
economic issues. Unfortunately, these details are unavai-
lable in the VSGNE dataset. Therefore, future research is
necessary to identify the barriers to proper medication uti-
lization. The Vascular Quality Initiative and the Society for
Vascular Surgery are in unique positions to promote such
quality efforts.22 Regional quality groups are well suited
to undertake quality improvement initiatives such as
increasing optimal medical management. As the VSGNE
has been able to demonstrate, a regional collaborative
effort can successfully improve clinical practice. This was
seen with increasing the use of patch closure during
CEA23 and increased beta-blockade utilization.24 Goingforward, appropriate perioperative AP and statin usage
will be a major quality initiative of the VSGNE.
Our study has several important limitations. Specif-
ically, the dosage of each medication is unknown. Also,
we are unable to determine the adherence to medication
utilization after discharge. Our data (not shown) demon-
strates that 84% of patients who were discharged on both
AP and statin agents remained on both at 1-year follow-
up. However, a third of patients had missing data points
in medication use at 1 year. This makes drawing any ﬁrm
conclusions difﬁcult. We do not have data beyond 1 year.
Second, due to the nature of the VSGNE dataset, we do
not have biochemistry data for each patient to evaluate
platelet response to AP agents or lipid and inﬂammatory
markers to assess the adequacy of statin treatment. Howev-
er, if many patients are being medically undertreated, this
would underestimate the potential effect of these medica-
tions. The true impact of optimal medical treatment may
actually be larger than we are able to identify in the present
study. Next, it is possible that our dataset has underre-
ported the number of patients intolerant to these agents.
Our analysis grouped patients intolerant to each medica-
tion with those not taking them for other reasons. This
was to identify the overall mortality beneﬁt of these agents.
Unfortunately, we are also unable to assess hemoglobin
A1c levels or blood pressure measurements, which are
also important in the medical management of these pa-
tients. Lastly, due to the observational nature of our data-
set, we can demonstrate association, but not causation for
optimal medical therapy and 5-year survival. Patients
were taking, or not taking, these medications for various
reasons, including socioeconomic, access to care, and other
contextual variables. This may affect a patient’s ability to
take optimal medical therapy for their cardiovascular dis-
ease and have an impact on their long-term survival. This
further emphasizes the need to ensure that each patient un-
dergoing vascular surgery is receiving optimal care to
obtain the best outcomes following vascular procedures.
In summary, this study shows that only 66% of patients
undergoing selected vascular operations were on optimal
medical management. There is wide variation in medica-
tion utilization among centers and procedures in New
England. Patients on optimal medical therapy had lower
30-day mortality and a statistically signiﬁcant improvement
in 5-year survival, resulting in an 18% absolute survival
beneﬁt at 5 years.
CONCLUSIONS
Despite the widespread acceptance of AP and statin
therapy among patients with PAD and cardiovascular dis-
ease, many patients remain on suboptimal therapy while
undergoing major vascular procedures. This variation is
associated with increased mortality following carotid inter-
ventions and lower extremity bypass, as well as aneurysm
repair. A relatively simple modiﬁcation in medical manage-
ment could have a potentially profound impact on patient
outcomes. Future quality improvement efforts need to
focus on identifying the factors associated with this level
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 6 De Martino et al 1621of variation. Additionally, understanding the barriers to
appropriate medication utilization should be identiﬁed to
ensure each patient undergoing interventions for vascular
disease is on optimal medical therapy.
AUTHOR CONTRIBUTIONS
Conception and design: RD, BN, DS, JC, PG
Analysis and interpretation: RD, JJ, BN, DS, JA, DB, JC,
PG
Data collection: RD, JJ, BN, DS, JA, DB, JC, PG
Writing the article: RD, JJ, JC, PG
Critical revision of the article: RD, JJ, BN, DS, JA, DB, JC,
PG
Final approval of the article: RD, JC, PG
Statistical analysis: RD, PG
Obtained funding: Not applicable
Overall responsibility: RD
REFERENCES
1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA,
Fowkes FG. Inter-Society Consensus for the Management of Periph-
eral Arterial Disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5-67.
2. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA,
Tuohy RJ, et al. Population-based randomised controlled trial on
impact of screening on mortality from abdominal aortic aneurysm. BMJ
2004;329:1259.
3. Hertzer NR, Beven EG, Young JR, O’Hara PJ, Ruschhaupt WF 3rd,
Graor RA, et al. Coronary artery disease in peripheral vascular patients.
A classiﬁcation of 1000 coronary angiograms and results of surgical
management. Ann Surg 1984;199:223-33.
4. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG,
Creager MA, Olin JW, et al. Peripheral arterial disease detection,
awareness, and treatment in primary care. JAMA 2001;286:1317-24.
5. Eldrup N, Budtz-Lilly J, Laustsen J, Bibby BM, Paaske WP. Long-term
incidence of myocardial infarct, stroke, and mortality in patients
operated on for abdominal aortic aneurysms. J Vasc Surg 2012;55:
311-7.
6. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA,
Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the
management of patients with peripheral arterial disease (lower ex-
tremity, renal, mesenteric, and abdominal aortic): a collaborative report
from the American Association for Vascular Surgery/Society for
Vascular Surgery, Society for Cardiovascular Angiography and In-
terventions, Society for Vascular Medicine and Biology, Society of
Interventional Radiology, and the ACC/AHA Task Force on Practice
Guidelines (Writing Committee to Develop Guidelines for the Man-
agement of Patients With Peripheral Arterial Disease): endorsed by the
American Association of Cardiovascular and Pulmonary Rehabilitation;
National Heart, Lung, and Blood Institute; Society for Vascular
Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease
Foundation. Circulation 2006;113:e463-654.
7. Subherwal S, Patel MR, Kober L, Peterson ED, Jones WS, Gislason GH,
et al. Missed opportunities: despite improvement in use of car-
dioprotective medications among patients with lower-extremity periph-
eral artery disease, underuse remains. Circulation 2012;126:1345-54.
8. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary pre-
vention and mortality in peripheral artery disease: National Health and
Nutrition Examination Study, 1999 to 2004. Circulation 2011;124:
17-23.
9. Cronenwett JL, Likosky DS, Russell MT, Eldrup-Jorgensen J,
Stanley AC, Nolan BW. A regional registry for quality assurance and
improvement: the: Vascular Study Group of Northern New England
(VSGNNE). J Vasc Surg 2007;46:1093-101; discussion: 1101-2.
10. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL,
et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of
patients with extracranial carotid and vertebral artery disease: executive
summary. A report of the American College of Cardiology Founda-
tion/American Heart Association Task Force on Practice Guidelines,
and the American Stroke Association, American Association of
Neuroscience Nurses, American Association of Neurological Surgeons,
American College of Radiology, American Society of Neuroradiology,
Congress of Neurological Surgeons, Society of Atherosclerosis Imaging
and Prevention, Society for Cardiovascular Angiography and In-
terventions, Society of Interventional Radiology, Society of Neuro-
Interventional Surgery, Society for Vascular Medicine, and Society for
Vascular Surgery. Circulation 2011;124:489-532.
11. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK,
et al. 2011 ACCF/AHA focused update of the guideline for the
management of patients with peripheral artery disease (updating the
2005 guideline): a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines: developed in collaboration with the Society for Cardio-
vascular Angiography and Interventions, Society of Interventional
Radiology, Society for Vascular Medicine, and Society for Vascular
Surgery. J Vasc Surg 2011;54:e32-58.
12. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery
occlusive disease: American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6
Suppl):815S-43S.
13. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA,
Franklin BA, et al. AHA/ACCF Secondary Prevention and Risk
Reduction Therapy for Patients with Coronary and other Atheroscle-
rotic Vascular Disease: 2011 update: a guideline from the American
Heart Association and American College of Cardiology Foundation.
Circulation 2011;124:2458-73.
14. De Martino RR, Nolan BW, Goodney PP, Chang CK, Schanzer A,
Cambria R, et al. Outcomes of symptomatic abdominal aortic aneu-
rysm repair. J Vasc Surg 2010;52:5-12.e1.
15. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al.
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL):
multicentre, randomised controlled trial. Lancet 2005;366:1925-34.
16. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT Jr,
Matsumura JS, Kohler TR, et al. Outcomes following endovascular vs
open repair of abdominal aortic aneurysm: a randomized trial. JAMA
2009;302:1535-42.
17. Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM,
Brooks W, et al. Stenting versus endarterectomy for treatment of
carotid-artery stenosis. N Engl J Med 2010;363:11-23.
18. Blackshear JL, Cutlip DE, Roubin GS, Hill MD, Leimgruber PP,
Begg RJ, et al. Myocardial infarction after carotid stenting and end-
arterectomy: results from the Carotid Revascularization Endarterec-
tomy versus Stenting Trial. Circulation 2011;123:2571-8.
19. Owens CD, Conte MS. Medical management of peripheral arterial
disease: bridging the “gap?”. Circulation 2012;126:1319-21.
20. NQF Measure 0465-Perioperative Anti-platelet Therapy for Patients
undergoing Carotid Endarterectomy. Available at: www.qualityforum.
org. Accessed November 26, 2012.
21. Million Hearts Initiative. Available at: http://millionhearts.hhs.gov/
index.html. Accessed January 20, 2013.
22. Cronenwett JL, Kraiss LW, Cambria RP. The Society for Vascular
Surgery Vascular Quality Initiative. J Vasc Surg 2012;55:1529-37.
23. Goodney PP, Nolan BW, Eldrup-Jorgensen J, Likosky DS,
Cronenwett JL. Restenosis after carotid endarterectomy in a multi-
center regional registry. J Vasc Surg 2010;52:897-904, 905 e1-2;
discussion: 904-5.
24. Goodney PP, Eldrup-Jorgensen J, Nolan BW, Bertges DJ, Likosky DS,
Cronenwett JL. A regional quality improvement effort to increase beta
blocker administration before vascular surgery. J Vasc Surg 2011;53:
1316-28.e1; discussion: 1327-8.
Submitted Oct 21, 2013; accepted Dec 3, 2013.
Additional material for this article may be found online
at www.jvascsurg.org.
Supplementary Fig (online only). Variation in optimal medical
therapy across Centers in the Vascular Study Group of New
England (VSGNE) for centers with >100 cases (2005-2012).
Supplementary Table (online only). Unadjusted survival in the Vascular Study Group of New England (VSGNE),
2005-2012
Suboptimal medical therapy at DC Optimal discharge medication at DC P Unadjusted HR P
All 70% (67%-73%) 79% (77%-81%) <.001 0.64 (0.58-0.73) <.001
CEA 76% (72%-81%) 83% (81%-85%) .002 0.73 (0.60-0.89) .002
CAS 52% (34%-68%) 70% (60%-78%) .211 0.71 (0.41-1.22) .214
oAAA 77% (70%-83%) 83% (77%-87%) .045 0.66 (0.44-0.99) .047
EVAR 71% (63%-77%) 75% (70%-80%) .004 0.64 (0.48-0.87) .004
Supraa 83% (73%-89%) 95% (92%-97%) .001 0.29 (0.13-0.65) .003
Infra 61% (56%-66%) 69% (65%-74%) .001 0.73 (0.60-0.89) .001
CAS, Coronary artery stenting; DC, discharge; EVAR, endovascular aneurysm repair; HR, hazard ratio; Infra, infrainguinal artery bypass; oAAA, open
abdominal aortic aneurysm repair; Optimal, on both antiplatelet and statin therapy at discharge; Suboptimal, either single agent or neither agent at discharge;
Supra, suprainguinal artery bypass.
aThree-year survival displayed. Suprainguinal bypass has only been tracked since 2009.
JOURNAL OF VASCULAR SURGERY
1621.e1 De Martino et al June 2014
